Dizal’s ZEGFROVY Outperforms Chemotherapy in NSCLC
SHANGHAI, China, May 29, 2026 Dizal has announced groundbreaking results from the global Phase 3 WU-KONG28 trial, demonstrating that...
Cancer Therapeutics
Advertisement
Servier’s VORANIGO® Delivers More Than 44 Months of Progression-Free Survival in IDH-Mutant Glioma
BOSTON, Massachusetts, May 31, 2026 Servier has announced extended follow-up results from the pivotal Phase 3 INDIGO trial, demonstrating...
Menarini Group Reports Promising Elacestrant-Capivasertib Results in Metastatic Breast Cancer at ASCO 2026
FLORENCE, Italy and NEW YORK, May 28, 2026 Menarini Group and its wholly owned subsidiary Stemline Therapeutics have announced...
TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Advertisements
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Pfizer and Innovent Forge $10.5B Global Oncology Alliance
NEW YORK, SAN FRANCISCO, and SUZHOU, China, May 28, 2026 Pfizer Inc. and Innovent Biologics have announced a landmark...
Nuvalent Expands Leadership in Precision Lung Cancer
CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...
Dizal Advances ZEGFROVY for EGFR Lung Cancer
SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...
Bayer’s Asundexian Wins FDA Priority Review
BERLIN, Germany, May 19, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry...
Advertisement
